AUTHORS
Qian Wang, Hao Ai2, Hongfei Wu, MD, PhD3, Ge Liu4, Xiaoqiang Zhao, N/A5, Xuewen Yang6, Xiaolin HAN7, Qingsong Yin, PhD8
AFFILIATIONS
1 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
2 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
3 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
4 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
5 The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
6 The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
7 The First Affiliated Hospital of Henan Medical University, Weihui, Henan, China
8 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
ABSTRACT
Background and Aim:
R-CHOP remains the standard first-line therapy for diffuse large B-cell lymphoma (DLBCL), yet 30–40% of patients progress. Pomalidomide is a third-generation immunomodulatory agent with more potent immunomodulatory effects than lenalidomide. However, the survival benefits and safety of pomalidomide-rituximab combination therapy in newly diagnosed DLBCL remain poorly characterized. Herein, we prospectively evaluated the efficacy and safety of pomalidomide combined with R-CHOP in newly diagnosed DLBCL, with particular attention to extranodal involvement.
Methods:
This single-arm, multicenter registry study (ChiCTR2600127766) enrolled patients aged 18–75 years with newly diagnosed DLBCL. All patients received pomalidomide (4 mg on days 1–14) plus R-CHOP (Rituximab, Cyclophosphamide, Epirubicin, Vincristine, Prednisone) every 21 days for 6–8 cycles, followed by pomalidomide maintenance at 2 mg on days 1–21 every 28 days. Response was assessed using the 2014 Lugano criteria every 2 cycles; complete response (CR) included CR, CRu, and complete metabolic response. Adverse events (AEs) were graded using NCI-CTCAE v5.0. The primary endpoint was overall response rate (ORR) (CR + partial response) at the end of induction. Secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response (DOR), and safety. Data cutoff was July 31, 2026.
Results:
From September 2024 to July 2026, 33 patients (median age 65 years, range 34–74) were enrolled across three centers. Eighteen (54.5%) were male, and 15 (45.5%) were female. Most patients presented with high-risk features: 22 (66.7%) had stage III–IV disease; 19 (57.6%) had an IPI score ≥3; 24 (72.7%) had a non-GCB subtype per the Hans algorithm; 9 (27.3%) had bulky disease (≥7.5 cm); 6 (18.2%) had bone marrow involvement; 13 (39.4%) had a double-expressor phenotype; and 20 (60.6%) had elevated LDH levels. Extranodal involvement was present in 28 patients (84.8%; median, 2 sites; range, 1–8). The most frequently involved extranodal sites were bone (n = 15), gastrointestinal tract (n = 10), soft tissue (n = 6), serosal surfaces (n = 5), skin (n = 4), and testis (n = 4).
Among the 29 evaluable patients who completed 2 treatment cycles, the ORR was 100%, and the CR rate was 20.7% (6/29). Among the 26 patients who completed 4 treatment cycles, the ORR was 96.2% (25/26), and the CR rate was 65.4% (17/26). The median time to response was 1.5 months, and the median time to achieve CR was 3.0 months. Among the 21 patients who completed induction therapy (19 completed all 6–8 cycles, 1 discontinued due to disease progression, and 1 declined further therapy after cycle 5), the ORR was 90.5% (19/21), and the CR rate was 85.7% (18/21). Progressive disease was documented in 2 patients. Among the 17 patients with extranodal involvement who completed induction, the ORR was 88.2% (15/17), and the CR rate was 82.4% (14/17). The CR rate was numerically lower in patients with IPI ≥3 versus <3 (81.8% vs. 90.0%), age >60 versus ≤60 years (78.6% vs. 100%), and ≥2 versus <2 extranodal sites (81.8% vs. 90.0%) (all P > 0.05).
At a median follow-up of 7.3 months, median OS, PFS, and DOR were not reached. The estimated 12-month OS and PFS rates were 91.8% (95% CI, 70.9–97.9) and 87.0% (95% CI, 64.6–95.6), respectively. Among the 28 patients with extranodal involvement, the estimated 12-month OS and PFS rates were 89.9% (95% CI, 65.3–97.4) and 84.0% (95% CI, 57.8–94.6), respectively. Two deaths occurred: one due to disease progression complicated by hemophagocytic syndrome, and one from virus infection. No treatment-related mortality was observed. Grade ≥3 AEs occurred in 26 patients (78.8%), all involving hematologic toxicity: lymphopenia 23 (69.7%), neutropenia 20 (60.6%), leukopenia 19 (57.6%), anemia 2 (6.1%), thrombocytopenia 2 (6.1%). Grade ≥3 non-hematologic toxicity occurred in 7 (21.2%): pneumonia 4 (12.1%); hyponatremia, constipation, and dizziness 1 each (3.0%).
Conclusions:
Pomalidomide with R-CHOP produced a high induction response rate in newly diagnosed DLBCL, including those with extranodal involvement, and had a manageable safety profile.
Fundings
This study was supported by the Henan Clinical Research-oriented Doctor Program (HNCRD202510) and (ITTA2412), and Zhongyuan Sci-Tech Innovation Leading Talents (244200510008).
Disclosures: All authors declare no conflicts of interest.
DISCLOSURES
Qian Wang: No relevant conflicts of interest to declare.